Fibromyalgia is a disorder identified by musculoskeletal pain, fatigue, sleep, memory and mood issues. The development of fibromyalgia has been implicated by infections and other stressors. These stressors could result in repeated reactivations of latent herpes virus infections, leading to the development of fibromyalgia. This study evaluated a new drug combination famciclovir + celecoxib (IMC-1) active against suspected herpes virus reactivation and infection, hence, used for cure of fibromyalgia.

Study of results proved that IMC-1 was efficacious and safe in treating symptoms of fibromyalgia, which supports the hypothesis that herpes virus infections can also contribute to this syndrome. The safety and efficacy of above combination was suggested by improved retention rates, decreased adverse event rates and evidence of efficacy on a broad spectrum of outcome measures.